Featured News
Charles River Partners with Wheeler Bio
Strategic agreement aims to support clients antibody development journey
Charles River has partnered with Wheeler Bio, an antibody contract development and manufacturing organization (CDMO), to help clients expedite their drug development journey from discovery and CMC development to manufacturing.
Our industry-leading experience in antibody discovery services, safety, and analytics, coupled with with Wheeler’s Portable CMC® platform, helps accelerate therapeutic discovery to IND submission timelines. This umbrella offering efficiently connects the preclinical, clinical manufacturing, and release testing journeys, significantly reducing the complexity of managing multiple vendor relationships. Integrating CMC development early in discovery enables therapeutic developers to collaborate with experts across the organizations to utilize phase-appropriate manufacturing and analytics. The services and expertise come together to provide a single concept-to-commercial offering.